M M Maxwell

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Two approaches to drug discovery in SOD1-mediated ALS
    Wendy J Broom
    Day Neuromuscular Research Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA
    J Biomol Screen 11:729-35. 2006
  2. ncbi RNAi applications in therapy development for neurodegenerative disease
    M M Maxwell
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard, Medical School, 114 16th Street, Room 3200, Charlestown, MA 02129, USA
    Curr Pharm Des 15:3977-91. 2009
  3. ncbi The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS
    Michele M Maxwell
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02115, USA
    Hum Mol Genet 20:3986-96. 2011
  4. ncbi New VAPB deletion variant and exclusion of VAPB mutations in familial ALS
    J E Landers
    Cecil B Day Laboratory for Neuromuscular Research, Massachusetts General Hospital East, Charlestown, MA, USA
    Neurology 70:1179-85. 2008
  5. ncbi Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments
    Myra Coufal
    Massachusetts Institute of Technology, Cambridge, MA, USA
    J Biomol Screen 12:351-60. 2007
  6. ncbi RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells
    Michele M Maxwell
    Day Laboratory for Neuromuscular Research and High Throughput Screening Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 101:3178-83. 2004
  7. ncbi Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18-505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
  8. ncbi Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells
    Stephen M Altmann
    Massachusetts General Institute for Neurodegenerative Disease and Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown, 02129, USA
    Chem Biol 13:765-70. 2006

Research Grants

  1. RNAi-mediated Silencing of Mutant Superoxide Dismutase
    MICHELE MAXWELL; Fiscal Year: 2006

Collaborators

Detail Information

Publications8

  1. ncbi Two approaches to drug discovery in SOD1-mediated ALS
    Wendy J Broom
    Day Neuromuscular Research Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA
    J Biomol Screen 11:729-35. 2006
    ..Ultimately, the authors believe that these 2 cell-based assays will provide powerful strategies to identify novel therapies for the treatment of inherited SOD1-associated forms of ALS...
  2. ncbi RNAi applications in therapy development for neurodegenerative disease
    M M Maxwell
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard, Medical School, 114 16th Street, Room 3200, Charlestown, MA 02129, USA
    Curr Pharm Des 15:3977-91. 2009
    ..It further describes current applications of RNAi techniques for target identification and validation studies and underscores the importance of this methodology to developing treatments for neurological diseases...
  3. ncbi The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS
    Michele M Maxwell
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02115, USA
    Hum Mol Genet 20:3986-96. 2011
    ....
  4. ncbi New VAPB deletion variant and exclusion of VAPB mutations in familial ALS
    J E Landers
    Cecil B Day Laboratory for Neuromuscular Research, Massachusetts General Hospital East, Charlestown, MA, USA
    Neurology 70:1179-85. 2008
    ..No additional mutations have been identified...
  5. ncbi Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments
    Myra Coufal
    Massachusetts Institute of Technology, Cambridge, MA, USA
    J Biomol Screen 12:351-60. 2007
    ..These compounds were subjected to a functional assay, which yielded a lead compound that rescues cells from induced mutant polyglutamine toxicity...
  6. ncbi RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells
    Michele M Maxwell
    Day Laboratory for Neuromuscular Research and High Throughput Screening Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 101:3178-83. 2004
    ..The present study further supports the therapeutic potential of RNAi-based methods for the treatment of inherited human diseases, including ALS...
  7. ncbi Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18-505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
    ....
  8. ncbi Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells
    Stephen M Altmann
    Massachusetts General Institute for Neurodegenerative Disease and Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown, 02129, USA
    Chem Biol 13:765-70. 2006
    ..The protective role of PARP1 inhibitors against oxidative stress has been shown in this model system...

Research Grants2

  1. RNAi-mediated Silencing of Mutant Superoxide Dismutase
    MICHELE MAXWELL; Fiscal Year: 2006
    ..In addition, the therapeutic potential of RNAi will be assessed using viral delivery of shRNA to the spinal cords of mutant SOD1 transgenic mice. ..